November 1, 2017

TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 59th American Society of Hematology Annual Meeting

Investor and Analyst Reception to be Held on Sunday December 10, 2017 at 8:00pm ET at the Ritz Carlton Atlanta (Downtown) with Presentations by Leading Clinical Investigators

NEW YORK, Nov. 01, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that updated data for TGR-1202 (umbralisib), the Company's once-daily PI3K delta inhibitor, and TG-1101 (ublituximab), the Company's novel glycoengineered anti-CD20 monoclonal antibody, have been selected for presentation at the upcoming 59th American Society of Hematology (ASH) annual meeting, to be held December 9-12, 2017, at the Georgia World Congress Center in Atlanta, Georgia. Abstracts are now available online and can be accessed on the ASH meeting website at www.hematology.org. Clinical abstract highlights as well as the details of clinical and preclinical posters to be presented at ASH are outlined below.

Clinical Abstract Highlights:

- ***TGR-1202 Integrated Analysis:*** *336 patients with relapsed/refractory Lymphoid Malignancies exposed to a TGR-1202 based regimen for upwards of 4+ years, demonstrated a favorable safety profile with infrequent Grade 3/4 adverse events prevalent amongst prior generation PI3K delta inhibitors: transaminitis (< 3%), colitis (< 1%), and pneumonitis (< 0.5%)*
- ***Kinase Inhibitor Intolerance Study:*** *In patients with Chronic Lymphocytic Leukemia (CLL) who are intolerant to prior BTK or PI3K delta inhibitor therapy, no patients (n=22) discontinued due to TGR-1202 intolerance with a median follow-up of 6 months*
- ***TG-1101 + TGR-1202 + PD-1 Triplet:*** *60% ORR (3 of 5) observed in BTK refractory CLL patients treated with the triple combination of TGR-1202 plus TG-1101 plus pembrolizumab*

Poster presentations at the ASH 2017 meeting include the following:

Sunday December 10, 2017:

- Title: Phase I/II Study of Pembrolizumab in Combination with Ublituximab (TG-1101) and Umbralisib (TGR-1202) in Patients with Relapsed/Refractory CLL
  - Abstract Number: 3010
  - Session: 642. CLL: Therapy, excluding Transplantation: Poster II
  - Date and Time: Sunday, December 10, 2017; 6:00 PM - 8:00 PM ET
  - Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2
  - Presenter: Anthony R. Mato, MD, University of Pennsylvania, Philadelphia, PA

- Title: Umbralisib/TGR-1202 as a Novel Dual PI3K/CK1 Inhibitor Has a Unique Therapeutic Role in Silencing Oncogenes in Aggressive Lymphomas
  - Abstract Number: 2809
  - Session: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster II
  - Date and Time: Sunday, December 10, 2017; 6:00 PM - 8:00 PM ET
  - Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2
  - Presenter: Ipsita Pal, PhD, Columbia University Medical Center, New York, NY

- Title: Differential Regulation of T Cells By PI3K Delta Inhibitors in a CLL Murine Model
  - Abstract Number: 3009
  - Session: 642. CLL: Therapy, excluding Transplantation: Poster II
  - Date and Time: Sunday, December 10, 2017; 6:00 PM - 8:00 PM ET
  - Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2
  - Presenter: Kamira K. Maharaj, BS, Moffit Cancer Center, Tampa, FL

Monday, December 11, 2017:

- Title: An Integrated Safety Analysis of the Next Generation PI3Kδ Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies
  - Abstract Number: 4037
  - Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III
  - Date and Time: Monday, December 11, 2017; 6:00 PM - 8:00 PM ET
  - Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2
  - Presenter: Matthew S. Davids, MD, Dana Farber Cancer Institute, Boston, MA

- Title: KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K-δ Inhibitor Therapy
  - Abstract Number: 4314
  - Session: 642. CLL: Therapy, excluding Transplantation: Poster III
  - Date and Time: Monday, December 11, 2017; 6:00 PM - 8:00 PM ET
  - Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2
  - Presenter: Anthony R. Mato, MD, University of Pennsylvania, Philadelphia, PA

- Title: PI3K-Delta Inhibitors Induce Primary Monocyte Cytotoxicity but Do Not Alter Monocyte Differentiation
  - Abstract Number: 4284
  - Session: 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster III
  - Date and Time: Monday, December 11, 2017; 6:00 PM - 8:00 PM ET
  - Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2
  - Presenter: Daphne Friedman, MD, Durham VA-Duke University Medical Center, Durham, NC

The above referenced abstracts can be viewed online through the ASH meeting website at www.hematology.org. Following each presentation, the data presented will be available on the Publications page of the Company's website at www.tgtherapeutics.com.

TG THERAPEUTICS INVESTOR & ANALYST EVENT

TG Therapeutics will also host a reception on Sunday, December 10, 2017 beginning at 8:00pm ET with featured presentations beginning promptly at 8:15pm ET. The event will take place at the Ritz Carlton Atlanta (Downtown) in the Congress Room. This event will be webcast live and will be available on the Events page, located within the Investors & Media section of the Company's website at www.tgtherapeutics.com, as well as archived for future review. This event will also be broadcast via conference call. To access the conference line, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), and reference Conference Title: TG Therapeutics December 2017 Investor & Analyst Event.

ABOUT TG THERAPEUTICS, INC.

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202, or the combination of which is referred to as "U2", are in Phase 3 clinical development for patients with hematologic malignancies, with TG-1101 also in Phase 3 clinical development for Multiple Sclerosis. Additionally, the Company has recently brought its anti-PD-L1 monoclonal antibody into Phase 1 development and aims to bring additional pipeline assets into the clinic in the future. TG Therapeutics is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. In addition to the risk factors identified from time to time in our reports filed with the Securities and Exchange Commission, factors that could cause our actual results to differ materially are the following: our ability to successfully and cost effectively complete preclinical and clinical trials; the risk that early clinical trial results, that may have supported the acceptance of our data for presentation or influenced our decision to proceed with additional clinical trials, will not be reproduced in future studies or in the final presentations; the risk that the combination of TG-1101 and TGR-1202, referred to as TG-1303 and being studied in the UNITY clinical trials, will not prove to be a safe and efficacious combination; the risk that any interim analyses from ongoing clinical trials will not produce the desired or predicted result. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information

found on our website is not incorporated by reference into this press release and is included for reference purposes only.

CONTACT:

Jenna Bosco
Vice President, Investor Relations
TG Therapeutics, Inc.
Telephone: 212.554.4351
Email: ir@tgtxinc.com

Source: TG Therapeutics, Inc.